Difference between revisions of "Part:BBa K1699005"
(→Characterization) |
|||
(15 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
− | |||
__NOTOC__ | __NOTOC__ | ||
<partinfo>BBa_K1699005 short</partinfo> | <partinfo>BBa_K1699005 short</partinfo> | ||
− | gRNA for dCas9-VP64 targeting synthetic activation promoter pMLPm under U6 promoter | + | gRNA for dCas9-VP64 targeting synthetic activation promoter pMLPm under the control of U6 (RNA polymerase III) promoter. gRNA sequence is complementary to 3 different loci in the synthetic promoter pMLPm (1), and gRNA-dCas9-VP64 complex can promote transcription downstream of a synthetic promoter. |
+ | |||
+ | |||
− | |||
===Usage and Biology=== | ===Usage and Biology=== | ||
+ | Guide RNA is a hundred base-long molecule with a unique two dimensional structure which binds dCas9-VP64 and guides it to a dsDNA sequence complementary to 21-22 base pairs on the 5' end of the molecule. Upon binding to promoter, dCas9-VP64-gRNA complex will promote transcription of genes downstream of binding site. gRNA scaffold sequence for Sp dCas9-VP64 was used (2). | ||
+ | |||
+ | ===Characterization=== | ||
+ | This part was designed as a control construct for two cancer-specific promoter-based design of CRISPR-mediated transcriptional activation. In the design, gRNA is ribozyme-flanked (to enable synthesis under RNA polymerase II promoter) and is under control of human survivin promoter. | ||
+ | |||
+ | '''U6-gMLP''': AAV vector for the synthesis of gRNA for dCas9-VP64 targeting synthetic activation promoter pMLPm (abbreviated as gMLP) under the control of human U6 promoter (Fig. 1). | ||
+ | |||
+ | [[Image:U6-gMLP-pAAV_Map.jpg|center|500px|thumb|'''Fig. 1'''. Plasmid map of AAV vector carrying gMLP under the control of human U6 promoter.]] | ||
+ | |||
+ | ===References=== | ||
+ | 1. Tunable and multifunctional eukaryotic transcription factors based on CRISPR/Cas. Farzadfard F, Perli SD, Lu TK. ACS Synth Biol. 2013 Oct 18;2(10):604-13. doi: 10.1021/sb400081r. Epub 2013 Sep 11. http://www.ncbi.nlm.nih.gov/pubmed/23977949 | ||
+ | |||
+ | 2. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, Thakore PI, Glass KA, Ousterout DG, Leong KW, Guilak F, Crawford GE, Reddy TE, Gersbach CA. Nat Methods. 2013 Oct;10(10):973-6. doi: 10.1038/nmeth.2600. Epub 2013 Jul 25. http://www.ncbi.nlm.nih.gov/pubmed/23892895 | ||
+ | |||
+ | |||
<!-- --> | <!-- --> |
Latest revision as of 12:16, 14 September 2015
gRNA for dCas9-VP64 targeting synthetic activation promoter pMLPm under U6 promoter
gRNA for dCas9-VP64 targeting synthetic activation promoter pMLPm under the control of U6 (RNA polymerase III) promoter. gRNA sequence is complementary to 3 different loci in the synthetic promoter pMLPm (1), and gRNA-dCas9-VP64 complex can promote transcription downstream of a synthetic promoter.
Usage and Biology
Guide RNA is a hundred base-long molecule with a unique two dimensional structure which binds dCas9-VP64 and guides it to a dsDNA sequence complementary to 21-22 base pairs on the 5' end of the molecule. Upon binding to promoter, dCas9-VP64-gRNA complex will promote transcription of genes downstream of binding site. gRNA scaffold sequence for Sp dCas9-VP64 was used (2).
Characterization
This part was designed as a control construct for two cancer-specific promoter-based design of CRISPR-mediated transcriptional activation. In the design, gRNA is ribozyme-flanked (to enable synthesis under RNA polymerase II promoter) and is under control of human survivin promoter.
U6-gMLP: AAV vector for the synthesis of gRNA for dCas9-VP64 targeting synthetic activation promoter pMLPm (abbreviated as gMLP) under the control of human U6 promoter (Fig. 1).
References
1. Tunable and multifunctional eukaryotic transcription factors based on CRISPR/Cas. Farzadfard F, Perli SD, Lu TK. ACS Synth Biol. 2013 Oct 18;2(10):604-13. doi: 10.1021/sb400081r. Epub 2013 Sep 11. http://www.ncbi.nlm.nih.gov/pubmed/23977949
2. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, Thakore PI, Glass KA, Ousterout DG, Leong KW, Guilak F, Crawford GE, Reddy TE, Gersbach CA. Nat Methods. 2013 Oct;10(10):973-6. doi: 10.1038/nmeth.2600. Epub 2013 Jul 25. http://www.ncbi.nlm.nih.gov/pubmed/23892895
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal AgeI site found at 250
- 1000COMPATIBLE WITH RFC[1000]